Prelude Therapeutics (PRLD) Interest Coverage Ratio (2019 - 2026)
Prelude Therapeutics (PRLD) reported Interest Coverage Ratio of 0.7 for Q1 2026, up 53.62% on a YoY basis from 0.46 in Q1 2025, and up 97.04% sequentially from 23.63 in Q4 2025.
Prelude Therapeutics (PRLD) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Prelude Therapeutics (PRLD) has 8 years of Interest Coverage Ratio data on file, last reported at 0.7 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 53.62% year-over-year to 0.7; the trailing twelve-month figure through Mar 2026 stood at 4.15 (up 31.96% YoY), and the FY2025 full-year result was 0.49, up 35.49% from the prior year.
- Interest Coverage Ratio rose to 0.7 in Q1 2026, from 23.63 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.3 in Q4 2022 to a low of 77.55 in Q4 2023.
- A 5-year average of 11.95 and a median of 2.51 in 2022 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio slumped 25696.43% in 2023 and soared 93.64% in 2024, its largest moves.
- Tracing PRLD's Interest Coverage Ratio over 5 years: stood at 0.3 in 2022, then sank by 25696.43% to 77.55 in 2023, then advanced by 18.0% to 63.59 in 2024, then soared by 62.83% to 23.63 in 2025, then soared by 97.04% to 0.7 in 2026.
- Business Quant data shows PRLD's Interest Coverage Ratio at 0.7 in Q1 2026, 23.63 in Q4 2025, and 0.95 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - | -0.70 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.70 |
| Dec 31, 2025 | -23.63 |
| Sep 30, 2025 | -0.95 |
| Jun 30, 2025 | -1.45 |
| Mar 31, 2025 | -1.51 |
| Dec 31, 2024 | -63.59 |
| Sep 30, 2024 | -0.82 |
| Jun 30, 2024 | -0.87 |
| Mar 31, 2024 | -0.79 |
| Dec 31, 2023 | -77.55 |
| Sep 30, 2023 | -12.84 |
| Jun 30, 2023 | -6.00 |
| Mar 31, 2023 | -3.20 |
| Dec 31, 2022 | -0.30 |
| Sep 30, 2022 | -2.51 |
| Jun 30, 2022 | -3.83 |
| Mar 31, 2022 | -2.68 |
| Dec 31, 2021 | -0.44 |
| Sep 30, 2021 | -0.22 |
| Jun 30, 2021 | -0.21 |